News

Genticel bags €18.2m
Enlarge image

BusinessFranceGermany

Genticel bags €18.2m

26.04.2013 - French vaccine specialist Genticel SA (Toulouse) has raised €18.2m in a financing round.

The round was led by Wellington Partners (Munich), which included all current institutional investors  such as IDInvest Partners, Edmond de Rothschild Investment Partners (Paris), InnoBio fund, IRDI and Amundi Private Equity Funds.   The company said it will use the new funds to push its two therapeutic vaccine candidates against the cancer-causing human papilloma virus subtypes HPV16 and HPV18.

Its ProCervix vaccine, which is built on Genticel’s CyaA antigen delivery technology, has successfully finished phase I clinical study. The phase I trial (n=47) revealed no dose limiting toxicity and no patient drop-out. In addition, ProCervix induced a dose-dependent immune response as well as viral clearance in a substantially larger percentage of patients as compared to placebo. ProCervix will enter into phase II development in order to demonstrate proof of efficacy. Genticel’s other pipeline product is a CyaA-based multivalent HPV vaccine with additional virus subtype coverage.    Currently, there is preventive HPV vaccination but still no effective treatment against established infection with high-risk HPV types albeit promising approaches.

Genticel’s vaccines are designed for the treatment of infected women who have not yet developed high-grade cervical lesions or cancer.    Recent estimates by the World Health Organization suggest that world-wide approximately 300 million women are carriers of HPV infection at any given time and approximately 500,000 patients are diagnosed with cervical cancer each year.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/genticel-bags-eur182m.html

BioeconomyEU

26.08.2015 In its second call for proposals, the Bio-Based Industries Joint Undertaking has earmarked €106m for the research and development of useful bio-based products.

OncologyNorway

25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.

LicensingUKSwitzerland

21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.

LicensingDenmark

18.08.2015 Danish Novo Nordisk is climbing on the antibody therapeutics bandwagon in a US$500m licensing agreement with antibody-specialist Genmab.

M&ASwitzerland

13.08.2015 Roche is stepping up its commitment in the fight against drug resistant “superbugs” with its takeover of US diagnostics play Geneweave, for up to US$425m.

M&AUK

11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.

Research and DevelopmentFranceGermany

07.08.2015 In a deal worth more than €300m, Sanofi has partnered up with German drug discovery and development company Evotec in order to develop beta cell-modulating diabetes therapies.

M&AIrelandUK

05.08.2015 Irish pharma and biotech major Shire wants to be number one in orphan diseases, and is setting out to acquire US-American Baxalta in a US$30bn deal – by any means necessary.

R&DUKSweden

04.08.2015 In a deal worth US$65m upfront, AstraZeneca is again teaming up with long-time partner Isis Pharmaceuticals Inc., this time to discover and develop RNA antisense drugs for cardiovascular, metabolic and renal diseases.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • NEUROVIVE PHARMACEUTICAL AB (S)23.00 SEK25.00%
  • BAVARIAN NORDIC (D)41.03 EUR20.85%
  • TIGENIX (B)1.02 EUR17.24%

FLOP

  • EVOCUTIS (UK)0.18 GBP-10.00%
  • BIOTIE THERAPEUTICS (FI)0.20 EUR-9.09%
  • THROMBOGENICS (B)2.90 EUR-6.15%

TOP

  • KARO BIO (S)38.10 SEK2281.2%
  • TRANSGENE (F)5.08 EUR80.8%
  • TIGENIX (B)1.02 EUR30.8%

FLOP

  • THROMBOGENICS (B)2.90 EUR-42.9%
  • BIONOR PHARMA (N)1.28 NOK-37.6%
  • WILEX (D)2.05 EUR-36.5%

TOP

  • KARO BIO (S)38.10 SEK4546.3%
  • ADOCIA (F)86.70 EUR432.2%
  • VERONA PHARMA (UK)4.92 GBP339.3%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-85.7%
  • BIOTEST (D)19.93 EUR-76.0%
  • NEOVACS (F)0.96 EUR-72.7%

No liability assumed, Date: 29.08.2015